Biocon’s pertuzumab biosimilar gets positive EMA CHMP opinion recommendation
Biocon Biologics says EMA CHMP issued a positive opinion recommending approval for its pertuzumab biosimilar under a tailored clinical approach.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.